StockData

IB Acquisition Corp. (IBACR) stock

IBACRNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends September 30Also trades as IBAC
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$0.10−0.00 (-3.50%)

Close on Oct 30, 2026Market cap $54.39MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$54.39M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$399.57K

Trading

Previous close
$0.11
Open
$0.10
Day's range
$0.10 – $0.10
Volume
200
Average volume (20 days)
2,731
Beta (5 years)
-0.01
52-week range
$10.19 – $11.64
RSI (14 days)
42.9
Volatility (1 year)
10.8%
WACC
7.5%

Market cap history

Month-end market cap since 2024, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.

PeriodIBACRS&P 500DifferenceIBACR per yearS&P 500 per year
1 month-8.9%-0.9%−8.0 pts
3 months-0.3%+2.1%−2.4 pts
Year to date+33.7%+11.7%+22.0 pts
1 year+61.0%+12.4%+48.6 pts

Four years at a glance

Fiscal years 2022 to 2025 and trailing twelve months, USD

Operating income

-$1.79M

Net income

-$399.57K-111.1% YoY
Reported periodTrailing twelve months

Press releases

Releases IB Acquisition filed with the SEC as exhibits to Form 8-K or 6-K

  1. 8-K exhibit EX-99.1
    News
  2. Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)
    Update
  3. 8-K exhibit EX-99.2
    Update
  4. 8-K exhibit EX-99.1
    News
  5. Report of Independent Registered Public Accounting Firm (PCAOB #1195)
    News
  6. 8-K exhibit EX-99.1
    News
All press releases and earnings

About IB Acquisition

Services-Commercial Physical & Biological Research

IB Acquisition Corp. is a blank check company established to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company maintains an opportunistic investment strategy without a restriction to a specific sector, though it focuses on high-growth businesses across fintech, healthcare and life sciences, sports and entertainment, and consumer goods. As an entity with no active operations, it provides prospective acquisition candidates with an alternative path to public markets and growth capital rather than selling direct commercial products or services to typical retail or enterprise end customers.

Company profile, executives and history

IB Acquisition stock: common questions

What is IB Acquisition's stock price?

IBACR closed at $0.10 on Oct 30, 2026, down 3.50% on the day. Over the past 52 weeks it traded between $10.19 and $11.64.

What is IB Acquisition's market cap?

IB Acquisition was worth $54.39M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.

Does IB Acquisition pay a dividend?

No. IB Acquisition has not paid a cash dividend over the last twelve months.

How has IBACR stock performed over the past year?

Including dividends, IBACR returned +61.0% over the past year, against +12.4% for the S&P 500.

Who are IB Acquisition's competitors?

Companies most similar to IB Acquisition by business, industry and size include FOXO, VSBC, BUDZ, ONMD, CBIH.